Clicky

Syndax Pharmaceuticals Inc(1T3)

Description: Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.


Keywords: Medicine Cancer Biopharmaceutical Clinical Medicine Drugs Treatment Of Cancer Monoclonal Antibodies Acute Myeloid Leukemia Orphan Drug Host Disease National Cancer Institute Entinostat Mixed Lineage Leukemia

Home Page: www.syndax.com

35 Gatehouse Drive
Waltham, MA 02451
United States
Phone: 781 419 1400


Officers

Name Title
Mr. Michael A. Metzger M.B.A. CEO & Director
Dr. Briggs W. Morrison M.D. Pres, Head of R&D and Director
Dr. Anjali Ganguli Ph.D. Chief Bus. Officer
Dr. Peter Ordentlich B.Sc., Ph.D. Co-Founder & Chief Scientific Officer
Dr. Richard A. Heyman Ph.D. Co-Founder
Dr. Ronald M. Evans Ph.D. Co-Founder, Advisor and Chair of Scientific Advisory Board
Dr. Michael Downes Ph.D. Co-Founder
Mr. Keith Alan Goldan CPA Chief Financial Officer
Mr. Alexander Nolte VP & Chief Accounting Officer
Sharon Klahre VP of Investor Relations & Communications

Exchange: F

Country: DE

Currency: Euro (€)

Forward PE: 0
Trailing PE: 125.2632
Price-to-Book MRQ: 4.082
Price-to-Sales TTM: 12.6994
IPO Date:
Fiscal Year End: December
Full Time Employees: 59
Back to stocks